Vertex Pharmaceuticals Incorporated, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets.
The company has approved medicines for cyst…
Analysis
Middle-of-the-road
Vertex Pharmaceuticals Incorporated sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is expensive. The owner-earnings multiple stands at 28.2×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 11% a year, against analyst forecasts of 13%. The price, in other words, assumes less than the experts do.
Growth is moderate; the safety picture is sturdy. The company scores 16/20 on our value-creation score: strong value creator.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202645
70
2026
All-time high
70
Jun 2026
All-time low
45
Mar 2026
Average rank
58
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
60
—
—
—
Price/Earnings
9
—
—
—
Price/Book
36
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
10
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.